We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Urology

Journal Scan / Research · August 10, 2022

Any Decline in PSA Levels Is Associated With Improved Survival in Patients With mCRPC Undergoing PSMA-Directed Radioligand Therapy

The Prostate


Additional Info

Disclosure statements are available on the authors' profiles:

The Prostate
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Prostate 2022 Jul 21;[EPub Ahead of Print], PE Hartrampf, FX Weinzierl, AK Seitz, H Kübler, M Essler, AK Buck, RA Werner, RA Bundschuh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading